JavaScript seems to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.

Human Apolipoprotein C-I (Apo C1) AssayMax™ELISA Kit

Human Apolipoprotein C-I (Apo C1) AssayMax™ELISA Kit

Move your mouse over image or click to enlarge

Human Apolipoprotein C-I (Apo C1) AssayMax™ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

View Datasheet

Cat#	Size	Price	Qty	Buy
EA8011-2	96 Well Plate	£276.25

Additional Information

Property	Value or Rating
Manufacturer	Assaypro, LLC.
Product Type	AssayMax™ ELISA Kits
Samples	Serum, Cell Culture
Species	Human
Reactivity	Human
Assay Format	Sandwich ELISA
Product Size	96 Well Plate
Range	0.031-2 ug/ml
Plex Number	1
Storage	Refer to component labels for details
Entrez Gene	341
Omim	107710
UniProt	P02654
UniGene	Hs.110675
Special Notes	For Research Use Only, Not To Be Used For Diagnostic Purposes
References	* Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 * Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 * Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 * Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014 " title=" * Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 * Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 * Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 * Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014 " target="_blank"> * Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400 * Cohen M et al. (2011) Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. PLoS One 6(1): e14540 * Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062 doi:10.1155/2011/271062 * Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014

Related Documents